Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Psoriatic Arthritis Topic Center

Featured Article

News
12/15/2023
Hannah Musick
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide...
12/15/2023
First Report Managed Care
News
11/15/2023

Lisa Kuhns, PhD

Lisa Kuhns, PhD
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients...
11/15/2023
First Report Managed Care
News
10/24/2023

Danielle Sposato

Danielle Sposato
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good...
10/24/2023
First Report Managed Care
News
09/12/2023
Jolynn Tumolo
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that...
09/12/2023
First Report Managed Care
News
08/22/2023
Jolynn Tumolo
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with...
08/22/2023
First Report Managed Care
News
07/27/2023
Jolynn Tumolo
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a...
07/27/2023
First Report Managed Care
News
06/16/2023
Jolynn Tumolo
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that...
06/16/2023
First Report Managed Care
News
05/18/2023
Jolynn Tumolo
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation...
05/18/2023
First Report Managed Care
News
04/21/2023
Jolynn Tumolo
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing...
04/21/2023
First Report Managed Care
News
03/16/2023
Jolynn Tumolo
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the...
03/16/2023
First Report Managed Care
News
10/27/2022
Edan Stanley
Utilizing Power Doppler ultrasound, researchers examined the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active psoriatic arthritis.
Utilizing Power Doppler ultrasound, researchers examined the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active psoriatic arthritis.
Utilizing Power Doppler...
10/27/2022
First Report Managed Care

Advertisement

Newsfeed

News
12/15/2023
Hannah Musick
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide...
12/15/2023
First Report Managed Care
News
11/15/2023

Lisa Kuhns, PhD

Lisa Kuhns, PhD
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients...
11/15/2023
First Report Managed Care
News
10/24/2023

Danielle Sposato

Danielle Sposato
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good...
10/24/2023
First Report Managed Care
News
09/12/2023
Jolynn Tumolo
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that...
09/12/2023
First Report Managed Care
News
08/22/2023
Jolynn Tumolo
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with...
08/22/2023
First Report Managed Care
News
07/27/2023
Jolynn Tumolo
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a...
07/27/2023
First Report Managed Care
News
06/16/2023
Jolynn Tumolo
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that...
06/16/2023
First Report Managed Care
News
05/18/2023
Jolynn Tumolo
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation...
05/18/2023
First Report Managed Care
News
04/21/2023
Jolynn Tumolo
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing...
04/21/2023
First Report Managed Care
News
03/16/2023
Jolynn Tumolo
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the...
03/16/2023
First Report Managed Care
News
09/20/2024
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment...
Explore the groundbreaking...
09/20/2024
First Report Managed Care
News
09/20/2024
Long-term acute care hospitals (LTCHs) provide critical, multidisciplinary care for medically complex patients, but survival rates and long-term functional outcomes remain poor, according to a study published in JAMA Network Open.
Long-term acute care hospitals (LTCHs) provide critical, multidisciplinary care for medically complex patients, but survival rates and long-term functional outcomes remain poor, according to a study published in JAMA Network Open.
Long-term acute care hospitals...
09/20/2024
First Report Managed Care
News
09/20/2024
Addressing stigma associated with pre-exposure prophylaxis (PrEP) is crucial for improving its uptake and adherence among eligible populations, according to study results published in Sexes.
Addressing stigma associated with pre-exposure prophylaxis (PrEP) is crucial for improving its uptake and adherence among eligible populations, according to study results published in Sexes.
Addressing stigma associated...
09/20/2024
First Report Managed Care
News
09/20/2024
As wildfires become an annual threat due to climate change, health systems must proactively adopt air quality-focused population health approaches to protect vulnerable patients with chronic respiratory conditions like COPD and asthma,...
As wildfires become an annual threat due to climate change, health systems must proactively adopt air quality-focused population health approaches to protect vulnerable patients with chronic respiratory conditions like COPD and asthma,...
As wildfires become an annual...
09/20/2024
First Report Managed Care
News
09/19/2024
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not...
09/19/2024
First Report Managed Care
News
09/16/2024
Obesity is associated with an increased cancer risk in patients with cardiovascular disease (CVD), highlighting the need for targeted prevention strategies, according to study results published in the Journal of the American Heart...
Obesity is associated with an increased cancer risk in patients with cardiovascular disease (CVD), highlighting the need for targeted prevention strategies, according to study results published in the Journal of the American Heart...
Obesity is associated with an...
09/16/2024
First Report Managed Care
News
09/16/2024
The Centers for Disease Control and Prevention (CDC) has awarded $400 million in funding to boost HIV prevention and surveillance efforts across the United States, aiming to accelerate progress in reducing new infections and improving health...
The Centers for Disease Control and Prevention (CDC) has awarded $400 million in funding to boost HIV prevention and surveillance efforts across the United States, aiming to accelerate progress in reducing new infections and improving health...
The Centers for Disease Control...
09/16/2024
First Report Managed Care
News
09/13/2024
The US Department of Health and Human Services (HHS) has announced updates to Medicare payments and policies to improve healthcare accessibility, equity, and quality for millions of Americans, according to a press release by the HHS.
The US Department of Health and Human Services (HHS) has announced updates to Medicare payments and policies to improve healthcare accessibility, equity, and quality for millions of Americans, according to a press release by the HHS.
The US Department of Health and...
09/13/2024
First Report Managed Care
News
09/10/2024
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results,...
09/10/2024
First Report Managed Care
News
09/10/2024
An investigational 4-factor prothrombin complex concentrate (4F-PCC) is as effective and safe as an FDA-approved 4F-PCC for rapidly reversing vitamin K antagonist (VKA) anticoagulation in patients requiring urgent surgery, according to a...
An investigational 4-factor prothrombin complex concentrate (4F-PCC) is as effective and safe as an FDA-approved 4F-PCC for rapidly reversing vitamin K antagonist (VKA) anticoagulation in patients requiring urgent surgery, according to a...
An investigational 4-factor...
09/10/2024
First Report Managed Care

Advertisement

Advertisement

Advertisement

Advertisement